Last Shot Hangover seems to be the big hope, nowadays. At CC time, Nuvilex had its very first case sold. 30% of projected revenues for 2009 depend on this product.

As for purEffect, CK41 is handling this on their own. Nuvilex may eventually get some royalties but none expected in the 2009 fiscal year. OraPhyte could be a good prospect but not this year either.

A CEO who is optimistic and seems to want and try to make this a success but, imo, there is still a long way to go. Today's drop in both volume and share price would seem to indicate the road to success could be very long indeed.

go